Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00.

Krystal Biotech Stock Performance

Shares of KRYS opened at $177.37 on Friday. The firm has a fifty day moving average of $163.08 and a 200-day moving average of $174.22. The company has a market cap of $5.11 billion, a price-to-earnings ratio of 59.32 and a beta of 0.87. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the business posted $0.30 EPS. Krystal Biotech’s revenue was up 116.4% on a year-over-year basis. Analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently made changes to their positions in KRYS. FMR LLC lifted its holdings in Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after purchasing an additional 21,133 shares during the period. Vanguard Group Inc. lifted its position in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC boosted its stake in Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. State Street Corp boosted its stake in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after acquiring an additional 11,411 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on KRYS. HC Wainwright reaffirmed a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a report on Friday, February 28th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).